Peptic ulcer secondary prevention: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Peptic ulcer}} | {{Peptic ulcer}} | ||
{{CMG}} | |||
==Overview== | |||
''Helicobacter pylori'' eradication alone was proved to be insufficient for secondary prevention of peptic ulcer bleeding, and therefore long-term proton pump inhibitor therapy is needed.<ref name="pmid11274623">{{cite journal| author=Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK et al.| title=Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. | journal=N Engl J Med | year= 2001 | volume= 344 | issue= 13 | pages= 967-73 | pmid=11274623 | doi=10.1056/NEJM200103293441304 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11274623 }} </ref><ref name="pmid11860399">{{cite journal| author=Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A et al.| title=Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. | journal=Aliment Pharmacol Ther | year= 2002 | volume= 16 | issue= 2 | pages= 167-80 | pmid=11860399 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11860399 }} </ref> FDA approved [[proton pump ihibitor]]s include [[lansoprazole]], [[omeprazole]], [[esomeprazole]], and [[rabeprazole]], which are indicated for risk reduction of duodenal ulcer recurrence. | |||
==Secondary Prevention== | |||
The following measures have been used in the secondary prophylaxis of peptic ulcer and its complications: | |||
* Stop NSAID | |||
* ''H. pylori'' erdication | |||
* Maintenance acid suppressive therapy | |||
* Acid-reducing surgical procedures | |||
==References== | ==References== | ||
Revision as of 16:05, 6 June 2014
|
Peptic ulcer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Surgery |
|
Case Studies |
|
2017 ACG Guidelines for Peptic Ulcer Disease |
|
Guidelines for the Indications to Test for, and to Treat, H. pylori Infection |
|
Guidlines for factors that predict the successful eradication when treating H. pylori infection |
|
Guidelines to document H. pylori antimicrobial resistance in the North America |
|
Guidelines for evaluation and testing of H. pylori antibiotic resistance |
|
Guidelines for when to test for treatment success after H. pylori eradication therapy |
|
Guidelines for penicillin allergy in patients with H. pylori infection |
|
Peptic ulcer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Peptic ulcer secondary prevention |
|
Risk calculators and risk factors for Peptic ulcer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Helicobacter pylori eradication alone was proved to be insufficient for secondary prevention of peptic ulcer bleeding, and therefore long-term proton pump inhibitor therapy is needed.[1][2] FDA approved proton pump ihibitors include lansoprazole, omeprazole, esomeprazole, and rabeprazole, which are indicated for risk reduction of duodenal ulcer recurrence.
Secondary Prevention
The following measures have been used in the secondary prophylaxis of peptic ulcer and its complications:
- Stop NSAID
- H. pylori erdication
- Maintenance acid suppressive therapy
- Acid-reducing surgical procedures
References
- ↑ Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK; et al. (2001). "Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen". N Engl J Med. 344 (13): 967–73. doi:10.1056/NEJM200103293441304. PMID 11274623.
- ↑ Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A; et al. (2002). "Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report". Aliment Pharmacol Ther. 16 (2): 167–80. PMID 11860399.